3LOUVET C,DE GRAMONT A.Role and value of oxaliplatin in metastatic colorectal cancers[J].Rev Med Interne,1997,18(4):368-371.
4BELIBERG H,DE GRAMONT A.Oxaliplatin plus 5-fluorouracil clinical experience in patients with advanced colorectal cancer[J].Semin Oncol,1998,25(Suppl5):32-39.
1Klauber N,Parangi S,Flynn E,et al. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibition I-methoxyestradionl and Paclitaxel [J] . Cancer Res, 1997,57 (1):81-82.
2王少华,杜冠华.肿瘤合理用药[M].北京:人民卫生出版社,2004.239-240.
3Raymond E, Faivre S, Woynarowski JM, et al. Oxaliplatin : Mechanism of action and antineopastic activety [ J ]. Semin Oncol, 1998, 25 (Suppl 5) :4 - 12.
4Louvet C, De gramant A. Role and value of oxaliplatin in metastatic colorectal cancers [J]. Rev Med Interne, 1997,18 (4) :368.
5Beliberg H ,de Gramont A. Oxaliplatin plus 5-fluorouracil: Clinical esperience in patients with advanced colorectal cancer [ J ]. Semin Oncol, 1998,25 ( Suppl 5 ) :32 - 39.
6Colucci G, Gebbia V, Paoletti G, et al. Phase Ⅲ Randomized Trial of FOLFIRI Versus FOLFOX4 in the Treatment of Advanced Colorectal Cancer: A Multicenter Study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol, 2005, 23(22): 4811-4814.
7Comella P, Massidda B, Filippelli G, et al. Oxaliplatin plus highdose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase Ⅲ trial. Ann Oncol, 2005, 16(6): 845-846.
8Delaunoit T, Goldberg RM, Sargent DJ. Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741. Cancer, 2004, 101(10): 2170-2176.
9Goldberg RM, Sargent DJ, Morton RF, et al. A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer. J Clin Oncol, 2004, 22(1): 4-6.
10Goldberg RM, Sargent DJ, Morton RF, et al. Randomized Controlled Trial of Reduced-Dose Bolus Fluorouracil Plus Leucovorin and Irinorecan or Infused Fluorouracil Plus Leucovorin and Oxaliplatin in Patients With Previously Untreated Metastatic Colorectal Cancer: A North American Intergroup Trial. J Clin Oncol, 2006, 24(21): 3347-3353.
5SEIKE M, MAETANI I, SAKAI Y. Treatment of malignant ascites in patients with advanced cancer: peritoneovenous shunt versus paracentesis[ J]. J Gastroenterol Hepatol, 2007,22 (12) : 2161 - 2166.
6SIDERIS L, MITCHELL A, DROLET P, et al. Surgical cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis arising from the appendix. [ J ]. Can J Surg, 2009, 52(2) : 135 -141.
7VAIRA M, CIOPPA T, D "AMICO S. Treatment of peritoneal carcinomatosis from colonic cancer by cytoreduction, peritonectomy and hyperthermic intraperitoneal chemotherapy ( HIPEC ) [ J ]. In Vivo,2010,24( 1 ) :79 -84.
8YANG XJ, HUANG CQ, SUO T. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival ofpatients with peritoneal carcinomatosis from gastric cancer: final results of a phase I randomized clinical trial [ J ]. Ann Surg Oncol,2011,18(6) : 1575 - 1581.
9Tomoda A,Miyazawa K,Tabuchi T.Prevention of carcinogenesis and development of gastric and colon cancers by2-aminophenoxazine-3-one(Phx-3):direct and indirect anti-cancer activity of Phx-3[J].Int J Mol Sci,2013,14(9):17573-17583.
10Wang L,Wu Y,Lin L,et al.Metastasis-associated in colon cancer-1upregulation predicts a poor prognosis of gastric cancer,and promotes tumor cell proliferation and invasion[J].Int J Cancer,2013,133(6):1419-1430.
